As global demand for vaccines grows, with the flu vaccine market set to reach US $ 20 billion in 2012, will the current novel H1N1 crisis become a turning point for Adimmune, or even the growth of the entire domestic vaccine industry?
在全球疫苗需求快速成長、流感疫苗市場更可望在 2012 年達到 200 億美元的情況下，這場新流感危機，會是國光生技、甚至是國內疫苗產業發展的契機嗎？